世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

核医学/放射性医薬品市場：種類別（診断用（SPECT-テクネチウム、PET-F-18）、治療用（ベータエミッター-I-131、アルファエミッター、ブラキセラピー-Y-90）、用途別（腫瘍学、心臓病学）、手順別） - 2026年までの世界予測


Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology,Cardiology), Procedures - Global Forecast to 2026

世界の核医学市場は、2021年の48億米ドルから2026年には75億米ドルに達すると予測され、予測期間中のCAGRは9.0%となります。核医学市場の成長は、主に、がんや心疾患の発生率や有病率の増加、Mo-99の需要と供給の... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2021年9月2日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		245 351 英語

※ 調査会社の事情により、予告なしに価格が変更になる場合がございます。
最新の価格はデータリソースまでご確認ください。
日本語のページは自動翻訳を利用し作成しています。


　

サマリー

世界の核医学市場は、2021年の48億米ドルから2026年には75億米ドルに達すると予測され、予測期間中のCAGRは9.0%となります。核医学市場の成長は、主に、がんや心疾患の発生率や有病率の増加、Mo-99の需要と供給のギャップを軽減するための取り組みなどの要因によるものです。しかし、放射性医薬品は半減期が短いため、潜在的な採用率は低く、また病院の予算削減や機器の価格高騰が市場の成長をある程度制限すると予想されます。
治療薬分野が最も高いCAGRで成長すると予想される
核医学市場は、タイプ別に診断用と治療用に分けられます。2020年の市場では、診断分野が大きなシェアを占めています。このセグメントの大きなシェアは、非侵襲性、心血管疾患の有病率の増加、早期診断に起因しています。

予測期間中、甲状腺アプリケーションセグメントが最も高い成長を示すと予想される
核医学市場は、アプリケーションに基づいて、SPECT、PET、治療用アプリケーションに分類されます。SPECTアプリケーションはさらに、心臓病、骨スキャン、甲状腺アプリケーション、肺スキャン、その他のSPECTアプリケーションに分けられます。予測期間では、甲状腺用途のセグメントが最も高い成長率を記録すると予測されています。このセグメントの高い成長率は、甲状腺疾患の発生率と有病率の増加に起因しています。
北米は2021年から2026年にかけて大きな成長を遂げると予測
2020年の核医学市場では、北米が最大のシェアを占めています。北米の大きなシェアは、この地域における放射性同位元素製造のための新技術の開発、政府の資金援助、企業の取り組みに起因していると考えられます。

サプライサイドの一次インタビューの内訳です。- 企業タイプ別。企業タイプ別：Tier1 - 64%、Tier2 - 23%、Tier3 - 13% - 職務上の地位別。Cレベル - 35%、ディレクターレベル - 25%、その他 - 40% - 地域別。地域別：北米 - 42%、欧州 - 21%、APAC - 26%、その他の地域 - 11
核医学分野で事業を展開している著名な企業には、Cardinal Health（米国）、GE Healthcare（米国）、Curium（フランス）、Lantheus Medical Imaging（米国）、Bayer AG（ドイツ）、Bracco Imaging（イタリア）、Eczacýbaþý-Monrol Nuclear Products（トルコ）、Nordion（カナダ）、Advanced Accelerator Applications（フランス）、NTP Radioisotopes（南アフリカ）などがあります。

調査範囲
このレポートでは、核医学市場をタイプ、アプリケーション、手順量、地域に基づいて調査しています。また、市場の成長に影響を与える要因（推進要因、抑制要因、機会、課題など）を調査しています。市場における機会と課題を分析し、市場リーダーの競争環境の詳細を提供しています。さらに、個別の成長トレンドに関してミクロ市場を分析し、主要4地域とそれぞれの国に関して市場セグメントの収益を予測しています。

このレポートを購入する主なメリット
本レポートは、様々なレベルの分析-業界動向、トッププレイヤーの市場シェア、企業プロファイルに焦点を当て、これらを合わせて基本的な見解を形成し、競合環境、高成長地域とそのドライバー、抑制、課題、機会を分析しています。本レポートは、既存の企業だけでなく、新規参入者や小規模な企業が市場の動向を把握し、より大きなシェアを獲得するために役立ちます。

ページTOPに戻る


目次

1 はじめに 35
1.1 調査の目的 35
1.2 市場の定義 35
1.2.1 市場の範囲 36
1.2.2 対象市場 37
1.2.3 調査対象年 38
1.3 通貨 38
1.4 制限事項 38
1.5 ステークホルダー 38
1.6 変更点のまとめ 39
2 調査方法 40
2.1 調査データ 40
2.2 調査方法のステップ 40
図1 調査方法：核医学市場 40
図2 リサーチデザイン 41
2.2.1 二次データ 42
2.2.1.1 二次資料 42
2.2.2 一次データ 43
図3 一次インタビューの内訳。企業タイプ別、呼称別、地域別 44
2.2.2.1 一次情報源 44
2.2.2.2 一次資料から得られた主な洞察 45
2.2.3 市場規模の推定方法 45
図4 調査方法：仮説の構築 46
2.2.4 レベニューマッピングに基づく市場規模の推定 45
2.3 市場データの推定と三角測量 48
図5：データの三角測量法 48
2.4 調査の前提条件 49
3 エグゼクティブサマリー 50
図6 核医学市場：タイプ別、2021年 vs. 2026年（単位：百万米ドル） 50
図7 眼鏡アプリケーション市場：タイプ別、2021年 vs. 2026年（百万米ドル） 51
図8：ペットアプリケーション市場：タイプ別、2021年 vs. 2026年（米ドル） 51
図9 核医学市場の地理的スナップショット 52
 
4 プレミアムインサイト 53
4.1 核医学市場の概要 53
図10 癌の高い罹患率が市場の成長を促進する 53
4.2 北アメリカ：核医学市場、タイプ別、国別（2020年） 54
図11 北米の核医学市場では、2020年に米国が最大のシェアを占めた 54
4.3 診断手順市場、タイプ別、2021年 vs. 2026年 54
図12 2026年の診断処置市場では、引き続き分光処置が主流となる 54
5 市場の概要 55
5.1 導入 55
5.2 市場力学 55
図13 核医学市場：推進要因、抑制要因、機会。
および課題 55
5.2.1 推進要因 56
5.2.1.1 対象疾患の発生率と有病率の増加 56
5.2.1.2 アルファ放射免疫療法に基づく標的がん治療法の開発 56
5.2.1.3 Mo-99の需要と供給のギャップを減らすための取り組み 56
5.2.2 阻害要因 57
5.2.2.1 放射性医薬品の半減期の短さ 57
5.2.3 機会 57
5.2.3.1 放射性医薬品の神経学的用途での使用 57
5.2.4 課題 57
5.2.4.1 病院の予算削減と設備コストの高騰 57
5.3 核医学/放射性医薬品市場におけるCovid-19の影響 58
5.4 バリューチェーン分析 58
図14 核医学／放射性医薬品市場のバリューチェーン分析 58
5.5 エコシステムの範囲 59
5.6 規制の状況 59
表1 核医学/放射性医薬品市場: 規制の状況 61
5.7 ポーターズ・ファイブフォース分析 63
5.7.1 ポーターズファイブフォース分析：核医学/放射性医薬品市場 63
5.8 特許分析 63
図15 過去10年間の特許出願件数の多い上位10社 図15 過去10年間の特許出願件数の多い上位10社 64
 
6 核医学・放射性医薬品市場（タイプ別） 65
6.1 導入 66
表2 核医学市場：タイプ別、2019-2026年（米ドル） 66
6.2 診断用核医学 66
表3：診断用核医学市場、タイプ別、2019-2026年 
(単位：百万米ドル) 66
表4：診断用核医学市場、地域別、2019-2026年 
(単位：百万米ドル) 67
表5 北アメリカ：診断用核医学市場、国別、2019年～2026年（米ドル） 67
表6 ヨーロッパ 診断用核医学市場、国別。
 2019-2026年 (百万米ドル) 67
表7 APAC: 診断用核医学市場、国別。
2019-2026年 (百万米ドル) 68
6.2.1 スペクトル放射性医薬品 68
表8 深刻なtc-99m不足に直面している一般的なtc-99mベースの診断手順の代替品 69
表9 スペクト放射性医薬品市場、タイプ別、2019-2026年 
(百万米ドル) 71
表10 スペクトル放射性医薬品市場：地域別、2019-2026年 
(単位：百万米ドル) 71
表11 北アメリカ：分光放射性医薬品市場、国別、2019年～2026年（USD 100万） 71
表12 ヨーロッパ：スペクトル放射性医薬品市場、国別。
2019年～2026年 (百万米ドル) 72
表13 APAC: スペクト放射性医薬品市場、国別。
2019-2026年 (US$百万) 72
6.2.1.1 Tc-99m 72
6.2.1.1 Tc-99mは2020年のSPECT放射性医薬品市場で最大のシェアを占めた 72
表14 Tc-99m市場、地域別、2019-2026年（米ドル） 73
表15 北アメリカ：Tc-99m市場、国別、2019年～2026年
(単位：百万米ドル) 73
表16 ヨーロッパ：Tc-99m市場、国別、2019-2026年 (US$百万) 73
表17 APAC: Tc-99m市場、国別、2019年～2026年 (US$百万) 74
6.2.1.2 I-123 74
6.2.1.2.1 放射線被曝の低減と患者の放射線誘発性がん発症リスクの低下がI-123の需要を牽引 74
表18 i-123市場：地域別、2019-2026年（百万米ドル） 74
表19 北アメリカ：I-123市場、国別、2019-2026年（米ドル） 75
表20 ヨーロッパ：i-123市場、国別、2019-2026年 (US$百万) 75
表21 APAC: i-123市場、国別、2019年-2026年 (US$百万) 75
6.2.1.3 Tl-201 76
6.2.1.3.1 TI-201はTc-99mの代替品となる可能性がある 76

　

ページTOPに戻る


　

Summary

The global nuclear medicine market is projected to reach USD 7.5 billion by 2026 from USD 4.8billion in 2021, at a CAGR of 9.0% during the forecast period. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.
Therapeutic segment is expected to grow at the highest CAGR
On the basis oftype, the nuclear medicine market is segmented into diagnostic and therapeutic. The diagnostic segment accounted for a larger share of the market 2020. The large share of this segment can be attributed to the non-invasiveness, increasing prevalence of cardiovascular diseases and early diagnosis.

Thyroid applications segment is expected to register the highest growth during the forecast period
Based on application, the nuclear medicine market is segmented into SPECT, PET, and therapeutic applications. The SPECT applications is further segmented into cardiology, bone scans, thyroid applications, pulmonary scans, and other SPECT applications. The thyroid applications segment is projected to register the highest growth rate in the forecast period. The high growth of this segment can be attributed to the increasing incidence and prevalence of thyroid disorders
North AmericaTo Witness Significant Growth From 2021 To 2026
In 2020, North America accounted for the largest share of the nuclear medicine market. A large share of North America can be attributed to The large share can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the region.

Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 64%, Tier 2 – 23%, and Tier 3 – 13% • By Designation: C-level – 35%, Director-level – 25%, and Others – 40% • By Region: North America - 42%, Europe – 21%, APAC –26%, Rest of the World –11%
Some of the prominent players operating in the nuclear medicine include Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacýbaþý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), and NTP Radioisotopes (South Africa).

Research Coverage
This report studies the nuclear medicinemarket based on type, application, procedure volume and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and respective countries.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 35
1.2.1 MARKET SCOPE 36
1.2.2 MARKETS COVERED 37
1.2.3 YEARS CONSIDERED FOR THE STUDY 38
1.3 CURRENCY 38
1.4 LIMITATIONS 38
1.5 STAKEHOLDERS 38
1.6 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
2.2 RESEARCH METHODOLOGY STEPS 40
FIGURE 1 RESEARCH METHODOLOGY: NUCLEAR MEDICINE MARKET 40
FIGURE 2 RESEARCH DESIGN 41
2.2.1 SECONDARY DATA 42
2.2.1.1 Secondary sources 42
2.2.2 PRIMARY DATA 43
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 44
2.2.2.1 Primary sources 44
2.2.2.2 Key insights from primary sources 45
2.2.3 MARKET SIZE ESTIMATION METHODOLOGY 45
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 46
2.2.4 REVENUE MAPPING-BASED MARKET ESTIMATION 46
2.3 MARKET DATA ESTIMATION AND TRIANGULATION 48
FIGURE 5 DATA TRIANGULATION METHODOLOGY 48
2.4 ASSUMPTIONS OF THE STUDY 49
3 EXECUTIVE SUMMARY 50
FIGURE 6 NUCLEAR MEDICINE MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 50
FIGURE 7 SPECT APPLICATIONS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 51
FIGURE 8 PET APPLICATIONS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 51
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE NUCLEAR MEDICINE MARKET 52
 
4 PREMIUM INSIGHTS 53
4.1 NUCLEAR MEDICINE MARKET OVERVIEW 53
FIGURE 10 HIGH PREVALENCE OF CANCER TO DRIVE MARKET GROWTH 53
4.2 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE AND COUNTRY (2020) 54
FIGURE 11 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN NUCLEAR MEDICINE MARKET IN 2020 54
4.3 DIAGNOSTIC PROCEDURES MARKET, BY TYPE, 2021 VS. 2026 54
FIGURE 12 SPECT PROCEDURES WILL CONTINUE TO DOMINATE THE DIAGNOSTIC PROCEDURES MARKET IN 2026 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
FIGURE 13 NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, 
AND CHALLENGES 55
5.2.1 DRIVERS 56
5.2.1.1 Increasing incidence and prevalence of target conditions 56
5.2.1.2 Development of alpha-radioimmunotherapy-based targeted cancer treatments 56
5.2.1.3 Initiatives to reduce the demand and supply gap of Mo-99 56
5.2.2 RESTRAINTS 57
5.2.2.1 Short half-life of radiopharmaceuticals 57
5.2.3 OPPORTUNITIES 57
5.2.3.1 Use of radiopharmaceuticals in neurological applications 57
5.2.4 CHALLENGES 57
5.2.4.1 Hospital budget cuts and high equipment costs 57
5.3 IMPACT OF COVID-19 ON THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 58
5.4 VALUE CHAIN ANALYSIS 58
FIGURE 14 VALUE CHAIN ANALYSIS OF THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 58
5.5 ECOSYSTEM COVERAGE 59
5.6 REGULATORY LANDSCAPE 59
TABLE 1 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: REGULATORY LANDSCAPE 61
5.7 PORTER’S FIVE FORCES ANALYSIS 63
5.7.1 PORTER’S FIVE FORCES ANALYSIS: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 63
5.8 PATENT ANALYSIS 63
FIGURE 15 TOP 10 COMPANIES WITH THE HIGHEST NO. OF PATENT APPLICATIONS IN THE LAST 10 YEARS 64
 
6 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE 65
6.1 INTRODUCTION 66
TABLE 2 NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION) 66
6.2 DIAGNOSTIC NUCLEAR MEDICINE 66
TABLE 3 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 
(USD MILLION) 66
TABLE 4 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY REGION, 2019–2026 
(USD MILLION) 67
TABLE 5 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 67
TABLE 6 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY,
 2019–2026 (USD MILLION) 67
TABLE 7 APAC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 68
6.2.1 SPECT RADIOPHARMACEUTICALS 68
TABLE 8 ALTERNATIVES TO COMMON TC-99M-BASED DIAGNOSTIC PROCEDURES IN THE FACE OF SEVERE TC-99M SHORTAGES 69
TABLE 9 SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 
(USD MILLION) 71
TABLE 10 SPECT RADIOPHARMACEUTICALS MARKET, BY REGION, 2019–2026 
(USD MILLION) 71
TABLE 11 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 71
TABLE 12 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 72
TABLE 13 APAC: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 72
6.2.1.1 Tc-99m 72
6.2.1.1.1 Tc-99m commanded the largest share of the SPECT radiopharmaceuticals market in 2020 72
TABLE 14 TC-99M MARKET, BY REGION, 2019–2026 (USD MILLION) 73
TABLE 15 NORTH AMERICA: TC-99M MARKET, BY COUNTRY, 2019–2026
(USD MILLION) 73
TABLE 16 EUROPE: TC-99M MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 73
TABLE 17 APAC: TC-99M MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 74
6.2.1.2 I-123 74
6.2.1.2.1 Reduced exposure to radiation and lower risk of patients developing radiation-induced cancer to drive the demand for I-123 74
TABLE 18 I-123 MARKET, BY REGION, 2019–2026 (USD MILLION) 74
TABLE 19 NORTH AMERICA: I-123 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 75
TABLE 20 EUROPE: I-123 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 75
TABLE 21 APAC: I-123 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 75
6.2.1.3 Tl-201 76
6.2.1.3.1 TI-201 can be a potential substitute to Tc-99m 76
TABLE 22 TI-201 MARKET, BY REGION, 2019–2026 (USD MILLION) 76
TABLE 23 NORTH AMERICA: TI-201 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 76
TABLE 24 EUROPE: TI-201 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 77
TABLE 25 APAC: TI-201 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 77
6.2.1.4 Ga-67 77
6.2.1.4.1 Long half-life of Ga-67 facilitates easy sales and distribution 77
TABLE 26 GA-67 MARKET, BY REGION, 2019–2026 (USD MILLION) 78
TABLE 27 NORTH AMERICA: GA-67 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 78
TABLE 28 EUROPE: GA-67 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 78
TABLE 29 APAC: GA-67 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 79
6.2.1.5 Other SPECT isotopes 79
TABLE 30 OTHER SPECT ISOTOPES MARKET, BY REGION, 2019–2026 (USD MILLION) 79
TABLE 31 NORTH AMERICA: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 80
TABLE 32 EUROPE: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2019–2026 
(USD MILLION) 80
TABLE 33 APAC: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2019–2026
(USD MILLION) 80
6.2.2 PET RADIOPHARMACEUTICALS 81
TABLE 34 PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2019–2026 (USD MILLION) 81
TABLE 35 PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2019–2026 
(USD MILLION) 81
TABLE 36 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 82
TABLE 37 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 82
TABLE 38 APAC: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 82
6.2.2.1 F-18 83
6.2.2.1.1 F-18 commanded the largest share of the PET radiopharmaceuticals market in 2020 83
TABLE 39 F-18 MARKET, BY REGION, 2019–2026 (USD MILLION) 83
TABLE 40 NORTH AMERICA: F-18 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 83
TABLE 41 EUROPE: F-18 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 84
TABLE 42 APAC: F-18 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 84
6.2.2.2 Rb-82 84
6.2.2.2.1 High accuracy offered by the Rb-82 isotope to support market growth 84
TABLE 43 RB-82 MARKET, BY REGION, 2019–2026 (USD MILLION) 85
TABLE 44 NORTH AMERICA: RB-82 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 85
TABLE 45 EUROPE: RB-82 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 85
TABLE 46 APAC: RB-82 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 86
6.2.2.3 Other PET isotopes 86
TABLE 47 OTHER PET ISOTOPES MARKET, BY REGION, 2019–2026 (USD MILLION) 86
TABLE 48 NORTH AMERICA: OTHER PET ISOTOPES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 86
TABLE 49 EUROPE: OTHER PET ISOTOPES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 87
TABLE 50 APAC: OTHER PET ISOTOPES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 87
6.3 THERAPEUTIC NUCLEAR MEDICINE 87
TABLE 51 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 87
TABLE 52 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY REGION, 
2019–2026 (USD MILLION) 88
TABLE 53 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, 
BY COUNTRY, 2019–2026 (USD MILLION) 88
TABLE 54 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 88
TABLE 55 APAC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 89
6.3.1 ALPHA EMITTERS 89
6.3.1.1 Ra-223 89
6.3.1.1.1 Easy production of Ra-223 is a key advantage driving market growth 89
TABLE 56 RA-223 MARKET, BY REGION, 2019–2026 (USD MILLION) 90
TABLE 57 NORTH AMERICA: RA-223 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 90
TABLE 58 EUROPE: RA-223 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 90
TABLE 59 APAC: RA-223 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 91
6.3.2 BETA EMITTERS 91
TABLE 60 BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 91
TABLE 61 BETA EMITTERS MARKET, BY REGION, 2019–2026 (USD MILLION) 91
TABLE 62 NORTH AMERICA: BETA EMITTERS MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 92
TABLE 63 EUROPE: BETA EMITTERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 92
TABLE 64 APAC: BETA EMITTERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 92
6.3.2.1 I-131 93
6.3.2.1.1 I-131 accounted for the largest share of the beta emitters market in 2020 93
TABLE 65 I-131 MARKET, BY REGION, 2019–2026 (USD MILLION) 93
TABLE 66 NORTH AMERICA: I-131 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 93
TABLE 67 EUROPE: I-131 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 94
TABLE 68 APAC: I-131 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 94
6.3.2.2 Y-90 94
6.3.2.2.1 Increasing applications in treating hepatocellular carcinoma to propel the growth of this segment 94
TABLE 69 Y-90 MARKET, BY REGION, 2019–2026 (USD MILLION) 95
TABLE 70 NORTH AMERICA: Y-90 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 95
TABLE 71 EUROPE: Y-90 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 95
TABLE 72 APAC: Y-90 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 96
6.3.2.3 Sm-153 96
6.3.2.3.1 Increasing incidence of bone metastasis to drive the growth of this segment 96
TABLE 73 SM-153 MARKET, BY REGION, 2019–2026 (USD MILLION) 96
TABLE 74 NORTH AMERICA: SM-153 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 96
TABLE 75 EUROPE: SM-153 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 97
TABLE 76 APAC: SM-153 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 97
6.3.2.4 Lu-177 97
6.3.2.4.1 Increasing incidence of neuroendocrine cancer is a key factor driving the growth of this segment 97
TABLE 77 LU-177 MARKET, BY REGION, 2019–2026 (USD MILLION) 98
TABLE 78 NORTH AMERICA: LU-177 MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 98
TABLE 79 EUROPE: LU-177 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 98
TABLE 80 APAC: LU-177 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 99
6.3.2.5 Re-186 99
6.3.2.5.1 Re-186 is commonly used for bone pain relief 99
TABLE 81 RE-186 MARKET, BY REGION, 2019–2026 (USD MILLION) 99
TABLE 82 NORTH AMERICA: RE-186 MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 99
TABLE 83 EUROPE: RE-186 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 100
TABLE 84 APAC: RE-186 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 100
6.3.2.6 Other beta emitters 100
TABLE 85 OTHER BETA EMITTERS MARKET, BY REGION, 2019–2026 (USD MILLION) 101
TABLE 86 NORTH AMERICA: OTHER BETA EMITTERS MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 101
TABLE 87 EUROPE: OTHER BETA EMITTERS MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 101
TABLE 88 APAC: OTHER BETA EMITTERS MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 102
6.3.3 BRACHYTHERAPY ISOTOPES 102
TABLE 89 BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2019–2026 (USD MILLION) 103
TABLE 90 BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2019–2026 (USD MILLION) 103
TABLE 91 NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 103
TABLE 92 EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 104
TABLE 93 APAC: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 104
6.3.3.1 I-125 104
6.3.3.1.1 I-125 accounted for the largest share of the brachytherapy isotopes market in 2020 104
TABLE 94 I-125 MARKET, BY REGION, 2019–2026 (USD MILLION) 104
TABLE 95 NORTH AMERICA: I-125 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 105
TABLE 96 EUROPE: I-125 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 105
TABLE 97 APAC: I-125 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 105
6.3.3.2 Ir-192 106
6.3.3.2.1 Ir-192 is used in treating prostate, skin, and oral cancer 106
TABLE 98 IR-192 MARKET, BY REGION, 2019–2026 (USD MILLION) 106
TABLE 99 NORTH AMERICA: IR-192 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 106
TABLE 100 EUROPE: IR-192 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 107
TABLE 101 APAC: IR-192 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 107
6.3.3.3 Pd-103 107
6.3.3.3.1 Pd-103 is best suited to treat aggressive tumors 107
TABLE 102 PD-103 MARKET, BY REGION, 2019–2026 (USD MILLION) 108
TABLE 103 NORTH AMERICA: PD-103 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 108
TABLE 104 EUROPE: PD-103 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 108
TABLE 105 APAC: PD-103 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 109
6.3.3.4 Cesium-131 109
6.3.3.4.1 Cs-131 is commonly used in gynecological applications 109
TABLE 106 CS-131 MARKET, BY REGION, 2019–2026 (USD MILLION) 109
TABLE 107 NORTH AMERICA: CS-131 MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 109
TABLE 108 EUROPE: CS-131 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 110
TABLE 109 APAC: CS-131 MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 110
6.3.3.5 Other brachytherapy isotopes 110
TABLE 110 OTHER BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 
2019–2026 (USD MILLION) 110
TABLE 111 NORTH AMERICA: OTHER BRACHYTHERAPY ISOTOPES MARKET, 
BY COUNTRY, 2019–2026 (USD MILLION) 111
TABLE 112 EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 111
TABLE 113 APAC: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 111
7 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION 112
7.1 INTRODUCTION 113
TABLE 114 NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 113
7.2 DIAGNOSTIC APPLICATIONS 113
TABLE 115 DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 113
7.2.1 SPECT APPLICATIONS 114
TABLE 116 SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 114
TABLE 117 SPECT APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION) 114
7.2.1.1 Cardiology 114
7.2.1.1.1 Rising incidence of CVD has increased the demand for cardiac diagnostic scans 114
TABLE 118 SPECT CARDIOLOGY APPLICATIONS MARKET, BY REGION, 
2019–2026 (USD MILLION) 115
7.2.1.2 Bone scans 115
7.2.1.2.1 Precision of SPECT in bone scans has driven the adoption of this technology 115
TABLE 119 SPECT BONE SCAN APPLICATIONS MARKET, BY REGION, 2019–2026 
(USD MILLION) 115
7.2.1.3 Thyroid 116
7.2.1.3.1 Introduction of dual SPECT/CT imaging is an important trend in the thyroid applications segment 116
TABLE 120 SPECT THYROID APPLICATIONS MARKET, BY REGION, 2019–2026 
(USD MILLION) 116
7.2.1.4 Pulmonary scans 116
7.2.1.4.1 SPECT/CT has shown high accuracy and sensitivity in pulmonary embolism applications 116
TABLE 121 SPECT PULMONARY SCAN APPLICATIONS MARKET, BY REGION, 
2019–2026 (USD MILLION) 117
7.2.1.5 Other SPECT applications 117
TABLE 122 OTHER SPECT APPLICATIONS MARKET, BY REGION, 
2019–2026 (USD MILLION) 117
7.2.2 PET APPLICATIONS 117
TABLE 123 PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 118
TABLE 124 PET APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION) 118
7.2.2.1 Oncology 118
7.2.2.1.1 Increasing incidence of cancer to propel market growth 118
TABLE 125 PET ONCOLOGY APPLICATIONS MARKET, BY REGION, 
2019–2026 (USD MILLION) 119
7.2.2.2 Cardiology 119
7.2.2.2.1 Growing preference for FDG in cardiac imaging to boost the market growth 119
TABLE 126 PET CARDIOLOGY APPLICATIONS MARKET, BY REGION, 
2019–2026 (USD MILLION) 119
7.2.2.3 Neurology 120
7.2.2.3.1 Increasing incidence of AD, epilepsy, and Parkinson’s disease is the major driver for the growth of the PET neurology market 120
TABLE 127 PET NEUROLOGY APPLICATIONS MARKET, BY REGION, 
2019–2026 (USD MILLION) 120
7.2.2.4 Other PET applications 120
TABLE 128 OTHER PET APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION) 120
7.3 THERAPEUTIC APPLICATIONS 121
TABLE 129 THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 121
TABLE 130 THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION) 121
7.3.1 THYROID INDICATIONS 122
7.3.1.1 Increasing prevalence of thyroid disorders to fuel market growth 122
TABLE 131 THERAPEUTIC APPLICATIONS MARKET FOR THYROID INDICATIONS, 
BY REGION, 2019–2026 (USD MILLION) 122
7.3.2 BONE METASTASIS 122
7.3.2.1 Introduction of novel therapies for bone metastasis will positively impact market growth 122
TABLE 132 THERAPEUTIC APPLICATIONS MARKET FOR BONE METASTASIS, BY REGION, 2019–2026 (USD MILLION) 123
7.3.3 ENDOCRINE TUMORS 123
7.3.3.1 The US dominates the therapeutic nuclear medicine market for endocrine tumor applications 123
TABLE 133 THERAPEUTIC APPLICATIONS MARKET FOR ENDOCRINE TUMORS, 
BY REGION, 2019–2026 (USD MILLION) 123
7.3.4 LYMPHOMA 124
7.3.4.1 Development of new isotopes for the treatment of lymphoma presents huge growth opportunities 124
TABLE 134 THERAPEUTIC APPLICATIONS MARKET FOR LYMPHOMA, BY REGION, 
2019–2026 (USD MILLION) 124
7.3.5 OTHER THERAPEUTIC APPLICATIONS 124
TABLE 135 OTHER THERAPEUTIC APPLICATIONS MARKET, BY REGION, 
2019–2026 (USD MILLION) 124
8 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: PROCEDURAL VOLUME ASSESSMENT 125
8.1 INTRODUCTION 126
TABLE 136 NUCLEAR MEDICINE MARKET, BY PROCEDURE, 
2019–2026 (THOUSAND PROCEDURES) 126
TABLE 137 NUCLEAR MEDICINE MARKET, BY REGION, 
2019–2026 (THOUSAND PROCEDURES) 126
8.2 DIAGNOSTIC PROCEDURES 127
8.2.1 HIGH PREVALENCE OF CANCER AND CARDIAC DISEASES TO DRIVE MARKET GROWTH 127
TABLE 138 DIAGNOSTIC PROCEDURES MARKET, BY TYPE, 2019–2026 
(THOUSAND PROCEDURES) 127
TABLE 139 DIAGNOSTIC PROCEDURES MARKET, BY REGION, 2019–2026 
(THOUSAND PROCEDURES) 127
8.2.2 SPECT PROCEDURES 128
TABLE 140 SPECT PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2026 
(THOUSAND PROCEDURES) 128
TABLE 141 SPECT PROCEDURES MARKET, BY REGION, 2019–2026
(THOUSAND PROCEDURES) 128
8.2.3 PET PROCEDURES 128
TABLE 142 PET PROCEDURES MARKET, BY RADIOISOTOPE, 2019–2026 
(THOUSAND PROCEDURES) 128
TABLE 143 PET PROCEDURES MARKET, BY REGION, 2019–2026 
(THOUSAND PROCEDURES) 129
 
8.3 THERAPEUTIC PROCEDURES 129
8.3.1 GROWING DEMAND FOR NON-INVASIVE METHODS TO SUPPORT MARKET GROWTH 129
TABLE 144 THERAPEUTIC PROCEDURES MARKET, BY TYPE, 2019–2026 
(THOUSAND PROCEDURES) 129
TABLE 145 THERAPEUTIC PROCEDURES MARKET, BY REGION, 2019–2026 
(THOUSAND PROCEDURES) 130
8.3.2 BETA-EMITTER PROCEDURES 130
TABLE 146 BETA-EMITTER PROCEDURES MARKET, BY RADIOISOTOPE, 
2019–2026 (THOUSAND PROCEDURES) 130
TABLE 147 BETA-EMITTER PROCEDURES MARKET, BY REGION, 2019–2026 
(THOUSAND PROCEDURES) 130
8.3.3 ALPHA-EMITTER PROCEDURES 131
TABLE 148 ALPHA-EMITTER PROCEDURES MARKET, BY REGION, 
2019–2026 (THOUSAND PROCEDURES) 131
8.3.4 BRACHYTHERAPY PROCEDURES 131
TABLE 149 BRACHYTHERAPY PROCEDURES MARKET, BY RADIOISOTOPE, 
2019–2026 (THOUSAND PROCEDURES) 131
TABLE 150 BRACHYTHERAPY PROCEDURES MARKET, BY REGION, 
2019–2026 (THOUSAND PROCEDURES) 131
9 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY REGION 132
9.1 INTRODUCTION 133
TABLE 151 NUCLEAR MEDICINE MARKET, BY REGION, 2019–2026 (USD MILLION) 133
9.2 NORTH AMERICA 133
FIGURE 16 NORTH AMERICA: NUCLEAR MEDICINE MARKET SNAPSHOT 134
TABLE 152 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 134
TABLE 153 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 135
TABLE 154 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, 
BY TYPE, 2019–2026 (USD MILLION) 135
TABLE 155 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, 
BY TYPE, 2019–2026 (USD MILLION) 135
TABLE 156 NORTH AMERICA: SPECT APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 136
TABLE 157 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 136
TABLE 158 NORTH AMERICA: PET APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 136
TABLE 159 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, 
BY TYPE, 2019–2026 (USD MILLION) 137
TABLE 160 NORTH AMERICA: BETA EMITTERS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 137
TABLE 161 NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 137
TABLE 162 NORTH AMERICA: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 138
9.2.1 US 138
9.2.1.1 The US dominates the North American nuclear medicine market 138
TABLE 163 US: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION) 139
TABLE 164 US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 139
TABLE 165 US: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 139
TABLE 166 US: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 140
TABLE 167 US: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 140
TABLE 168 US: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 140
TABLE 169 US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 141
TABLE 170 US: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 141
TABLE 171 US: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 141
TABLE 172 US: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 142
9.2.2 CANADA 142
9.2.2.1 Investments to secure medical isotope supply are likely to boost the market growth 142
TABLE 173 CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 142
TABLE 174 CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 143
TABLE 175 CANADA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 143
TABLE 176 CANADA: SPECT APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 143
TABLE 177 CANADA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 144
TABLE 178 CANADA: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 144
TABLE 179 CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 144
TABLE 180 CANADA: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 145
TABLE 181 CANADA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 145
TABLE 182 CANADA: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 145
9.3 ASIA PACIFIC 146
FIGURE 17 APAC: NUCLEAR MEDICINE MARKET SNAPSHOT 146
TABLE 183 APAC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 147
TABLE 184 APAC: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION) 147
TABLE 185 APAC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 147
TABLE 186 APAC: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 148
TABLE 187 APAC: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 148
TABLE 188 APAC: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 148
TABLE 189 APAC: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 149
TABLE 190 APAC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 149
TABLE 191 APAC: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 149
TABLE 192 APAC: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 150
TABLE 193 APAC: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 150
9.3.1 JAPAN 150
9.3.1.1 Japan dominates the APAC nuclear medicine market 150
TABLE 194 JAPAN: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION) 151
TABLE 195 JAPAN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 151
TABLE 196 JAPAN: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 151
TABLE 197 JAPAN: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 152
TABLE 198 JAPAN: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 152
TABLE 199 JAPAN: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 152
TABLE 200 JAPAN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 153
TABLE 201 JAPAN: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 153
TABLE 202 JAPAN: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 153
TABLE 203 JAPAN: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 154
9.3.2 CHINA 154
9.3.2.1 High incidence of cancer and stroke to support market growth in China 154
TABLE 204 CHINA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION) 154
TABLE 205 CHINA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 155
TABLE 206 CHINA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 155
TABLE 207 CHINA: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 155
TABLE 208 CHINA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 156
TABLE 209 CHINA: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 156
TABLE 210 CHINA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 156
TABLE 211 CHINA: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 157
TABLE 212 CHINA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 157
TABLE 213 CHINA: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 157
9.3.3 REST OF ASIA PACIFIC 158
TABLE 214 ROAPAC: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION) 158
TABLE 215 ROAPAC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 158
TABLE 216 ROAPAC: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 159
TABLE 217 ROAPAC: SPECT APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 159
TABLE 218 ROAPAC: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 159
TABLE 219 ROAPAC: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 160
TABLE 220 ROAPAC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 160
TABLE 221 ROAPAC: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 160
TABLE 222 ROAPAC: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 161
TABLE 223 ROAPAC: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 161
9.4 EUROPE 161
TABLE 224 EUROPE: NUCLEAR MEDICINE MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 162
TABLE 225 EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION) 162
TABLE 226 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 163
TABLE 227 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 163
TABLE 228 EUROPE: SPECT APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 163
TABLE 229 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 164
TABLE 230 EUROPE: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 164
TABLE 231 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 164
TABLE 232 EUROPE: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 165
TABLE 233 EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 165
TABLE 234 EUROPE: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 165
9.4.1 GERMANY 166
9.4.1.1 Well-established healthcare system in Germany is a major factor supporting market growth 166
TABLE 235 GERMANY: NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 166
TABLE 236 GERMANY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 166
TABLE 237 GERMANY: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 167
TABLE 238 GERMANY: SPECT APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 167
TABLE 239 GERMANY: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 167
TABLE 240 GERMANY: PET APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 168
TABLE 241 GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 168
TABLE 242 GERMANY: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 168
TABLE 243 GERMANY: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 169
TABLE 244 GERMANY: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 169
9.4.2 FRANCE 169
9.4.2.1 France has a favorable reimbursement scenario for nuclear imaging 169
TABLE 245 FRANCE: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION) 170
TABLE 246 FRANCE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 170
TABLE 247 FRANCE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 170
TABLE 248 FRANCE: SPECT APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 171
TABLE 249 FRANCE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 171
TABLE 250 FRANCE: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 171
TABLE 251 FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 172
TABLE 252 FRANCE: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 172
TABLE 253 FRANCE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 172
TABLE 254 FRANCE: THERAPEUTIC APPLICATIONS MARKET, BY INDICATION, 
2019–2026 (USD MILLION) 173
9.4.3 UK 173
9.4.3.1 Rising demand for nuclear imaging and growing awareness to drive market growth in the UK 173
TABLE 255 UK: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION) 173
TABLE 256 UK: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 174
TABLE 257 UK: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 174
TABLE 258 UK: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 174
TABLE 259 UK: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 175
TABLE 260 UK: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 175
TABLE 261 UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 175
TABLE 262 UK: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 176
TABLE 263 UK: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 176
TABLE 264 UK: THERAPEUTIC APPLICATIONS MARKET, BY TYPE,
2019–2026 (USD MILLION) 176
9.4.4 ITALY 177
9.4.4.1 Growing prevalence of cancer and CVD to drive market growth in Italy 177
TABLE 265 ITALY: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION) 177
TABLE 266 ITALY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 177
TABLE 267 ITALY: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 178
TABLE 268 ITALY: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 178
TABLE 269 ITALY: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 178
TABLE 270 ITALY: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 179
TABLE 271 ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 179
TABLE 272 ITALY: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 179
TABLE 273 ITALY: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 180
TABLE 274 ITALY: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 180
9.4.5 SPAIN 180
9.4.5.1 Initiatives by SEMNIM will have a positive impact on the nuclear medicine market in Spain 180
TABLE 275 SPAIN: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION) 181
TABLE 276 SPAIN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 181
TABLE 277 SPAIN: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 181
TABLE 278 SPAIN: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 182
TABLE 279 SPAIN: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 182
TABLE 280 SPAIN: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 182
TABLE 281 SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 183
TABLE 282 SPAIN: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 183
TABLE 283 SPAIN: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 183
TABLE 284 SPAIN: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 184
9.4.6 ROE 184
TABLE 285 ROE: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION) 184
TABLE 286 ROE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 185
TABLE 287 ROE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 185
TABLE 288 ROE: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 185
TABLE 289 ROE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 186
TABLE 290 ROE: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 186
TABLE 291 ROE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 186
TABLE 292 ROE: BETA EMITTERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 187
TABLE 293 ROE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 187
TABLE 294 ROE: THERAPEUTIC APPLICATIONS MARKET, BY TYPE,
2019–2026 (USD MILLION) 187
9.5 REST OF THE WORLD 188
TABLE 295 ROW: NUCLEAR MEDICINE MARKET, BY TYPE, 2019–2026 (USD MILLION) 188
TABLE 296 ROW: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 189
TABLE 297 ROW: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 189
TABLE 298 ROW: SPECT APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 189
TABLE 299 ROW: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 190
TABLE 300 ROW: PET APPLICATIONS MARKET, BY TYPE, 2019–2026 (USD MILLION) 190
TABLE 301 ROW: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 
2019–2026 (USD MILLION) 190
TABLE 302 ROW: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 191
TABLE 303 ROW: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 
2019–2026 (USD MILLION) 191
10 COMPETITIVE LANDSCAPE 192
10.1 OVERVIEW 192
FIGURE 18 KEY DEVELOPMENTS IN THE NUCLEAR MEDICINE MARKET 192
10.2 MARKET RANKING ANALYSIS 192
FIGURE 19 NUCLEAR MEDICINE MARKET: MARKET RANKING, 2020 193
10.3 REVENUE ANALYSIS OF KEY MARKET PLAYERS 194
FIGURE 20 REVENUE SHARE ANALYSIS OF KEY PLAYERS 194
10.4 COMPANY EVALUATION MATRIX 194
10.4.1 STARS 195
10.4.2 EMERGING LEADERS 195
10.4.3 PERVASIVE PLAYERS 195
10.4.4 PARTICIPANTS 195
FIGURE 21 NUCLEAR MEDICINE MARKET: COMPANY EVALUATION MATRIX (2020) 196
 
10.5 COMPETITIVE LEADERSHIP MAPPING – START-UPS/SMES 197
10.5.1 PROGRESSIVE COMPANIES 197
10.5.2 STARTING BLOCKS 197
10.5.3 RESPONSIVE COMPANIES 197
10.5.4 DYNAMIC COMPANIES 197
FIGURE 22 NUCLEAR MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES 198
10.6 COMPETITIVE BENCHMARKING 199
10.6.1 OVERALL FOOTPRINT OF KEY PLAYERS 199
TABLE 304 OVERALL FOOTPRINT OF KEY PLAYERS 199
TABLE 305 REGIONAL FOOTPRINT OF KEY PLAYERS 199
TABLE 306 PRODUCT FOOTPRINT OF KEY PLAYERS 199
10.7 COMPETITIVE SCENARIO 200
10.7.1 PRODUCT LAUNCHES & APPROVALS 200
TABLE 307 KEY PRODUCT LAUNCHES & APPROVALS 200
10.7.2 DEALS 200
TABLE 308 KEY DEALS 200
11 COMPANY PROFILES 202
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
11.1 MAJOR PLAYERS 202
11.1.1 CURIUM 202
TABLE 309 CURIUM: BUSINESS OVERVIEW 202
11.1.2 BRACCO IMAGING S.P.A. 205
TABLE 310 BRACCO IMAGING S.P.A.: BUSINESS OVERVIEW 205
11.1.3 PHARMALOGIC 207
TABLE 311 PHARMALOGIC: BUSINESS OVERVIEW 207
11.1.4 ECZACIBAŞI-MONROL NUCLEAR PRODUCTS 209
TABLE 312 ECZACIBAŞI-MONROL NUCLEAR PRODUCTS: BUSINESS OVERVIEW 209
11.1.5 CARDINAL HEALTH 211
TABLE 313 CARDINAL HEALTH: BUSINESS OVERVIEW 211
FIGURE 23 CARDINAL HEALTH: COMPANY SNAPSHOT (2020) 212
11.1.6 NTP RADIOISOTOPES SOC LTD. (A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION) 214
TABLE 314 NTP RADIOISOTOPES SOC LTD.: BUSINESS OVERVIEW 214
11.1.7 GE HEALTHCARE 216
TABLE 315 GE HEALTHCARE: BUSINESS OVERVIEW 216
FIGURE 24 GE HEALTHCARE: COMPANY SNAPSHOT (2020) 217
11.1.8 NORDION INC. (A SOTERA HEALTH COMPANY) 219
TABLE 316 NORDION INC.: BUSINESS OVERVIEW 219
11.1.9 ADVANCED ACCELERATOR APPLICATIONS (AAA) (A PART OF NOVARTIS) 221
TABLE 317 ADVANCED ACCELERATOR APPLICATIONS: BUSINESS OVERVIEW 221
11.1.10 NORTHSTAR MEDICAL RADIOISOTOPES, LLC 223
TABLE 318 NORTHSTAR MEDICAL RADIOISOTOPES LLC: BUSINESS OVERVIEW 223
11.1.11 ECKERT & ZIEGLER 225
TABLE 319 ECKERT & ZIEGLER: BUSINESS OVERVIEW 225
FIGURE 25 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2020) 226
11.1.12 JOINT STOCK COMPANY ISOTOPE (JSC ISOTOPE) 228
TABLE 320 JOINT STOCK COMPANY ISOTOPE (JSC ISOTOPE): BUSINESS OVERVIEW 228
11.1.13 BAYER AG 230
TABLE 321 BAYER AG: BUSINESS OVERVIEW 230
FIGURE 26 BAYER AG: COMPANY SNAPSHOT (2020) 231
11.1.14 SIEMENS HEALTHINEERS 233
TABLE 322 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW 233
11.1.15 JUBILANT DRAXIMAGE, INC. (A SUBSIDIARY OF JUBILANT PHARMA) 234
TABLE 323 JUBILANT DRAXIMAGE, INC.: BUSINESS OVERVIEW 234
11.1.16 LANTHEUS MEDICAL IMAGING, INC. 236
TABLE 324 LANTHEUS MEDICAL IMAGING, INC.: BUSINESS OVERVIEW 236
FIGURE 27 LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT (2020) 236
11.2 OTHER PLAYERS 238
11.2.1 GLOBAL MEDICAL SOLUTIONS 238
11.2.2 SHINE MEDICAL TECHNOLOGIES 238
11.2.3 ISOTOPIA MOLECULAR IMAGING LTD. 239
11.2.4 SINOTAU PHARMACEUTICAL GROUP 240
11.2.5 INSTITUTE OF ISOTOPES CO., LTD. 241
11.2.6 CHINA ISOTOPE & RADIATION CORPORATION 242
11.2.7 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD. 242
11.2.8 CYCLOPHARM 243
11.2.9 IRE ELIT 243
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
12 APPENDIX 244
12.1 DISCUSSION GUIDE 244
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 250
12.3 AVAILABLE CUSTOMIZATIONS 252
12.4 RELATED REPORTS 252
12.5 AUTHOR DETAILS 253

 

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療/ヘルスケア）の最新刊レポート

MarketsandMarkets社のその他分野での最新刊レポート

本レポートと同じKEY WORD（diagnostic）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22　10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.